Associated Papers
TP53 c.730G > A pathogenic variant as a plausible candidate biomarker in pancreatic ductal adenocarcinoma patients from Karachi, pakistan: a retrospective cohort study.
Ali SMA et al.
Bmc Cancer, 2025
Impact of cancer therapy on clonal hematopoiesis mutations and subsequent clinical outcomes.
Nead KT et al.
Blood Advances, 2024
38830141 (PubMed )
Supplement: BLOODA_ADV-2024-012929-mmc1.xlsx › STable_2
Somatic mutations in 3929 HPV positive cervical cells associated with infection outcome and HPV type.
Pinheiro M et al.
Nature Communications, 2024
39266536 (PubMed )
Supplement: 41467_2024_51713_MOESM5_ESM.xlsx › Data_2
Mutation patterns in recurrent and/or metastatic oropharyngeal squamous cell carcinomas in relation to human papillomavirus status.
Reder H et al.
Cancer Medicine, 2021
33527763 (PubMed )
Supplement: CAM4-10-1347-s006.pdf
Genomic Landscape in Neoplasm-Like Stroma Reveals Distinct Prognostic Subtypes of Pancreatic Ductal Adenocarcinoma.
Jiang J et al.
Frontiers in Oncology, 2021
34733795 (PubMed )
Supplement: Table_1.xlsx › Sheet1
RAS and RHO family GTPase mutations in cancer: twin sons of different mothers?
Hodge RG et al.
Critical Reviews in Biochemistry and Molecular Biology, 2020
Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers.
De Marchi F et al.
Archives of Pathology & Laboratory Medicine, 2019
Clinical mutational profiling of 1006 lung cancers by next generation sequencing.
Illei PB et al.
Oncotarget, 2017
29228562 (PubMed )
Supplement: oncotarget-08-96684-s001.pdf
Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
Kovaleva V et al.
Molecular Cancer, 2016
27756406 (PubMed )
Supplement: 12943_2016_549_MOESM2_ESM.xlsx › Kovaleva_SuppTableS4_BMC_MolCan
Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy.
Nemecek R et al.
Oncotargets and Therapy, 2016
Clinical detection and categorization of uncommon and concomitant mutations involving BRAF.
Zheng G et al.
Bmc Cancer, 2015
Limited copy number-high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies.
Do H et al.
Molecular Cancer, 2009
Select a paper to view details